Effect of fluocinolone acetonide 0.2 μg/day implant on the decision to drive in patients with diabetic macular oedema: a report from the FAME study

OBJECTIVE: This study aimed to determine whether treatment with the 0.2 µg/day fluocinolone acetone implant (FAc; ILUVIEN, Alimera Sciences) and the associated improvements in best-corrected visual acuity (BCVA) and central subfield thickness (CST) demonstrated in the Fluocinolone Acetonide in Diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Grewal, Dilraj S, Fletcher, Donald C, Hariprasad, Seenu M, Suner, Ivan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936565/
https://www.ncbi.nlm.nih.gov/pubmed/31909197
http://dx.doi.org/10.1136/bmjophth-2019-000405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936565/
https://www.ncbi.nlm.nih.gov/pubmed/31909197
http://dx.doi.org/10.1136/bmjophth-2019-000405

Ejemplares similares